<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852692</url>
  </required_header>
  <id_info>
    <org_study_id>CR108945</org_study_id>
    <secondary_id>54179060GVH4001</secondary_id>
    <nct_id>NCT04852692</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants</brief_title>
  <official_title>A Retrospective/Prospective, Multicenter, Non-interventional, Historical Control Study Investigating Comparative Effectiveness of IMBRUVICA in Steroid Dependent/Refractory cGVHD Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Korea, Ltd., Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Korea, Ltd., Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of ibrutinib compared to&#xD;
      conventional salvage treatments in participants with steroid dependent/refractory chronic&#xD;
      graft versus host disease (cGVHD) by measuring overall cGVHD response (modified National&#xD;
      Institutes of Health [NIH] response defined complete response [CR] and partial response [PR])&#xD;
      at Week 24.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 9, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Part A and Part B: Percentage of Participants with Overall Response Rate</measure>
    <time_frame>Week 24</time_frame>
    <description>Overall response rate is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) according to modified National Institutes of Health (NIH) response.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part B: Rate of Sustained Response</measure>
    <time_frame>At least 5 months (up to 36 weeks)</time_frame>
    <description>Sustained response rate will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Duration of Response</measure>
    <time_frame>Up to 5 months</time_frame>
    <description>Duration of response will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A and Part B: Corticosteroid Requirement Changes Over Time</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>The change of the corticosteroid dose requirement during the treatment will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Time to cGVHD Progression</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Time to chronic graft versus host disease (cGVHD) progression is defined as the time from the first dose of the ibrutinib to modified NIH response defined progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Change in Lee cGVHD Symptom Scale</measure>
    <time_frame>Up to 36 weeks</time_frame>
    <description>Change in Lee cGVHD symptom scale will be assessed. It is a participant reported improvement in symptom burden.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">224</enrollment>
  <condition>Chronic Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Part A: Retrospective Phase</arm_group_label>
    <description>Retrospective collection of data for eligible participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) who initiated salvage treatments from initiation point (administration starting point of the salvage treatment) of the identified last-line of conventional salvage therapy for cGVHD treatment as their second-forth line therapy and will be collected for up to 24 weeks from the initiation point.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Prospective Phase</arm_group_label>
    <description>Prospectively enroll participants with steroid dependent/refractory cGVHD that are decided to be treated with ibrutinib in second-fourth line therapy for the treatment of cGVHD. Participants will continue to receive corticosteroids as a standard of care.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with steroid dependent or refractory chronic graft versus host disease (cGVHD)&#xD;
        will be included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Part A and Part B&#xD;
&#xD;
          -  Must have a confirmed diagnosis of steroid dependent or refractory classic cGVHD&#xD;
             defined at any time post-hematopoietic cell transplantation (HCT) as: a) refractory&#xD;
             disease - progressive cGVHD manifestations requiring prednisolone at greater than or&#xD;
             equal to (&gt;=) 1 milligram per kilogram per day (mg/kg/day) for at least 1 week or&#xD;
             persist without improvement despite continued treatment with glucocorticoid&#xD;
             (prednisolone at &gt;= 0.5 mg/kg/day or 1 mg/kg every other day) for at least 4 weeks; b)&#xD;
             dependent disease: persistent cGVHD manifestations requiring glucocorticoid &gt;=&#xD;
             prednisolone 0.25 mg/kg/day or &gt;=0.5mg/kg every other day for at least 8 weeks Part A&#xD;
&#xD;
          -  Treated at least 2 or more therapies for cGVHD (including glucocorticoids)&#xD;
&#xD;
          -  Participants whose identified last line of conventional salvage treatment is&#xD;
             second-fourth line of therapy&#xD;
&#xD;
          -  Index date (initiation date of the identified last-line of conventional salvage&#xD;
             therapy) at least 28 weeks before the study initiation date Part B&#xD;
&#xD;
          -  Treated at least 3 lines therapies for cGVHD (including glucocorticoids)&#xD;
&#xD;
          -  Participants who are treated with ibrutinib in their second-fourth line of therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Part A and Part B&#xD;
&#xD;
          -  Known or suspected active acute GVHD&#xD;
&#xD;
          -  Received an investigational drug (including investigational vaccines) or used an&#xD;
             invasive investigational medical device within 28 days Part A&#xD;
&#xD;
          -  Treated with an investigational agent for their identified last-line of conventional&#xD;
             salvage therapy&#xD;
&#xD;
          -  Pregnant, breastfeeding during last-line of conventional salvage therapy Part B&#xD;
&#xD;
          -  Pregnant, breast-feeding, or of childbearing potential without a negative serum or&#xD;
             urine pregnancy test within 7 days of enrollment. Male or female participants of&#xD;
             childbearing potential unwilling to use effective contraceptive precautions throughout&#xD;
             the trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Korea, Ltd., Korea Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Korea, Ltd., Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon-Si</city>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108945</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>April 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic</keyword>
  <keyword>Ibrutinib</keyword>
  <keyword>Retrospective</keyword>
  <keyword>Prospective</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

